Kornimate/medical-research-clean huggingface dataset:
safety study of kudiezi(yueanxin,a chinese medicine injection)used in hospitals in china

Conditions: Coronary Heart Disease; Angina Pectoris; Stroke

Summary: this study was advocated by institute of basic research in clinical medicine,china academy of chinese medical sciences in october 2011. it was funded by china major scientific and technological specialized specialized project for 'significant new formulation of net drugs'. kudiezi(yueanxin) is kind of chinese medicine injiection used for treating corinary heart diswese、angina pectoris and stroke in many chinese hospitals. the purpose of this study is to determine adverse drug events or adverse drug reaction in large sample size 30,000 patients.

it is very common that chinese medicine injection used in hospitals in mainland china.however safety problems rose in recent years.there could be many uncertain factors influence chinese medincine injection in clinical practice. safety surveillance on chinese medincine injection is an important problem that needs to be sorted out through large sample observational dtudy. a registry study for kudiezi(yueanxin) injection safety surveillance with 30000 patients will be conducted form jan.2012 to dec.2015. eligiblity crteria patients who will use kudiezi(yueanxin) injection in selected hospitals. date will be collected in four aspects by four different forms as following: form a(blue):demographic information ;form b(yellow):adverde drug events/reaction;form c(white):extracted information from hodpiral information system and laboratory information system.

Eligibility criteria:
inclusion criteria: patients using kudiezi(yueanxin) injection from 2012 to 2014 exclusion criteria: none
feasibility of physical activity in older adults with haematological malignancies: acces study

Conditions: Geriatric; Haematologic Neoplasm

Summary: the aim of this study is to implement a simple and unsupervised home-based physical activity (pa) program for cancer patients in 2 oncogeriatric units in toulouse hospital (day hospital and week hospital).

cancer treatments can cause side effects such as fatigue and reduced muscle function. studies have shown the benefits of physical activity, including reduced fatigue and improved quality of life. moreover, pa is often recommended for cancer survivors rather than patients undergoing treatment. it is essential to develop adapted, unsupervised, home-based pa programs to ensure access to pa for all cancer patients, particularly those living in rural areas or who have difficulty accessing healthcare. the pa program create is a simple, unsupervised pa program based on patients' functional capacities. depending on the patient's functional capacity, one of 7 pa programs will be prescribed by the doctor. the patient must perform the program independently for 6 months. telephone follow-ups (weeks 1, 2, 4, 6, 9, 12, 16, 20, et 24) as well as a monthly in-person follow-up visit will be made to adjust the prescription.

Eligibility criteria:
inclusion criteria: * suffering from a hematological malignancy (myelodysplasia, leukemia of any type, lymphoma, myeloma) * patient affiliated to a social security insurance * patient undergoing or scheduled chemotherapy (\< 3 months) and/or immunotherapy and/or targeted therapy. exclusion criteria: * life expectancy estimated at less than 3 months by the unit doctor; * cognitive impairment (not allowing comprehension of the physical activity program and research project) defined by mini-mental state examination (mmse) \<20/30; * patient included in a clinical trial that potentially interferes with the study objective (geriatric interventional study, early drug study, study modifying the patient's lifestyle habits).; * acute health problem (fever, severe anemia, intense pain, etc.) limiting the possibility of involvement in the program; * contraindication to physical activity; * patient under legal protection (guardianship or curatorship or safeguard of justice); * refusal of patient or primary caregiver to participate.

Keywords: older adults cancer physical activity deconditioning sedentarity aging-well
idmet (radico cohort) (radico-idmet)

Conditions: Silver Russell Syndrome; Beckwith-Wiedemann Syndrome; Transient Neonatal Diabetes Mellitus; Angelman Syndrome; Prader-Willi Syndrome; Temple Syndrome; Kagami-Ogata Syndrome; Pseudohypoparathyroidism; Familial Precocious Puberty

Summary: the goal of this observational study is to describe the natural history of imprinting disorders (ids) according to their metabolic profile in all patients (adults and children) affected with an id regardless of the severity of the disease, with a molecular characterization, with a signed informed consent for all subjects, followed in one partner's center. the main questions it aims to answer are: * can we identify common metabolic profiles for all imprinted diseases? * which imprinting disorders have an impact on the metabolic profiles of ids? * which are the metabolic risks associated to ids? * can we use the metabolic profiles for the clinical classification and prognosis of ids? * are there common therapeutic approaches for all ids?


Eligibility criteria:
inclusion criteria: * patients (adults and children) affected with an id regardless of the severity of the disease * a confirmed diagnosis of id (based on molecular diagnosis) * a signed informed consent for adults or signed informed consent of parents/guardians of minors/ protected adult. non-inclusion criteria: there are no non-inclusion criteria.
microcurrent treatment for chronic debilitating pain

Conditions: Pain; Opioid Use

Summary: to compare the efficacy of standard pain treatment and placebo (a microcurrent faux treatment) as opposed to standard pain treatment and microcurrent therapy in any primary care patients over a three month period.

this study is not intended to be definitive and should be considered an exploratory randomized trial to determine conditions for which microcurrent is more effective. thus, extensive subgroup analyses will be performed so that definitive trials can be developed. this is a single-blind study where subjects will not know if they are receiving microcurrent treatment.

Eligibility criteria:
\*\*patients must be able to get care at nellis air force base (a military installation) in order to participate in this study\*\* inclusion criteria: * male and female active duty members and dod beneficiaries * age 18 years or older * chronic debilitating pain * promis-57 t score is 60 or above exclusion criteria: * pregnant * implanted pacemaker * spinal cord stimulator * illicit drug use including marijuana use * epilepsy or a history of seizures * other implanted device (e.g., insulin pump, opioid pump, or defibrillator) * chronic debilitating pain referred or recruited as measured by promis-57 t score is below 60
intravenous-morphine and glucagon-usage enhanced mr cholangiography

Conditions: Liver Disease

Summary: morphine can induce constriction of sphincter of oddi and glucagon can facilitate bile secretion and dilatation of bile duct. we conduct this randomized double blinded study to evaluate the effect of enhancement in mrcp using intravenous morphine and glucagon.

morphine can induce constriction of sphincter of oddi and glucagon can facilitate bile secretion and dilatation of bile duct. we conduct this randomized double blinded study to evaluate the effect of enhancement in mrcp using intravenous morphine and glucagon.

Eligibility criteria:
inclusion criteria: * normal volunteer * living liver donor exclusion criteria: * copd * chronic liver disease * hypersensitive to glucagon * dm * insulinoma * glucagonoma * pregnancy
preimplantation genetic screening (pgs) in advanced female age and male severe factor

Conditions: Embryo Aneuploidies; Implantation Rates; Infertility

Summary: preimplantation genetic screening (pgs) is used for the selection of chromosomally normal embryos before the transfer in ivf treatments in many cases. there is great debate in the scientific community as to whether this is an efficient practice in patients of different prognosis. this prospective and randomized study seeks to study the results of chromosomal diagnosis using the new comparative genomic hybridization (cgh) arrays technique by practicing preimplantation genetic screening (pgs) in day three biopsy on one arm of the study and not on the other arm in order to compare the results. the investigators will study the ongoing pregnancy rate of each oocyte retrieval and the ongoing implantation rate with day 5 embryos (blastocysts) in ivf/ intracytoplasmic sperm injection (icsi) treatments of embryos from two different groups of patients: advanced age female patients (38 - 41 years of age) and male severe factor (≥2 million spermatozoids/ml.).

the randomized controlled trial results of advanced maternal age was completed and published (rubio et al., fertility\&sterility 2017). the randomized controlled trial results of the male factor indication was terminated with anticipation due to the change of the technology that prevented recruitment of patients using the old technology (that one used in the study).

Eligibility criteria:
inclusion criteria: advanced age and severe male factor: * women's age: 38- 41 years old (both included) * men's age: 18-60 years old (both included) * ovulation triggered with human chorionic gonadotrophin (hcg) (ovitrelle, merck-serono, madrid) * number of oocytes metaphase ii (mii): ≥ 5 (fresh, not vitrified) * quality of semen: ≥ 5 millions spermatozoids/ml exclusion criteria: advanced age and severe male factor: * number of oocytes metaphase ii (mii): \<5 oocytes * number of oocytes obtained: \>20 * estradiol on the day of human chorionic gonadotrophin (hcg) \>3000 pgr/ml administration. * progesterone on the day of hcg \>1,5 pmol/l administration * ≥ 2 previous miscarriages:biochemical,clinical,ectopic or a combination) * any un corrected alteration in a previous study. * other indications of (preimplantation genetic diagnosis.screening) pgd-s, such as monogenic illnesses, translocations, repeated implantation failure, repeated miscarriages, etc.

Keywords: pgs cgh aneuploidy advanced maternal age male factor
functional genomics of rare genetic diseases: realization of innovative tools with high diagnostic power

Conditions: Rare Diseases

Summary: the project aims to improve the understanding of a significant group of rare diseases both from a genetic/diagnostic and clinical/experimental point of view and aims to develop one or more diagnostic protocols. the study will be conducted through the application of complementary experimental strategies, ranging from the clinical, genetic and molecular characterization of the pathology to the search for rare variants and the development of cellular disease models.

1. clinical evaluation of patients and relatives 2. high throughput analysis of genetic variants in genome exomes 3. genotype-phenotype association testing 4. identification of genetic risk variants for rare diseases

Eligibility criteria:
inclusion criteria: * patients affected by: sla, incontinentia pigmenti type ii, rett syndrome, paget disease, pompe disease, immunodeficiency, centromeric instability and facial anomalies, cortical malformations and malignant epileptic encephalopathies exclusion criteria: * none
orientation agnosia: clinical and anatomical study

Conditions: Cerebrovascular Disorders; Brain Lesions

Summary: the area of the brain responsible of visuospatial processing data and more specifically the orientation of an object or image is located in parietal lobe, especially on the right side. a dysfunction of this region would result in a disorder of recognition of the orientation of objects and images that the investigators call orientation agnosia. several isolated cases are reported in the literature but to the investigators knowledge deficit has never been systematically searched, or put into perspective compared to other neuropsychological deficits. moreover, the precise location of the lesion responsible for such a disorder remains uncertain. the objectives of this study are (1) detect the existence of orientation agnosia in case of right parietal lesion, and (2) to improve the understanding of such a deficit allowing better management of this disorder.

idem

Eligibility criteria:
inclusion criteria: * age between 18 and 80 years * french language * right parietal lesion on cerebral imaging (ct-scan is sufficient), including stroke,arterial malformation, isolated tumoral lesion * informed consent exclusion criteria: * previous neurological history except non complicated migraine and stabilized epilepsia without seizure since 5 years * previous psychiatric history except depression without hospitalization \> one week or anxiety with maximum one anxiolytic treatment * drug or alcohol abuse * severe cranial traumatism * other severe chronic pathology * psychotropic medication other than a hypnotic or an anxiolytic at low doses without dose modification for at least one month * visual impairment * motor or sensory deficit sufficient to render impossible neuropsychological tests * patient without judicial or administrative liberty * measure of legal protection or no capable to express their consent * pregnancy or breastfeeding

Keywords: stroke parietal lesions
the clinical value of fa in ahlri patients

Conditions: Lower Respiratory Tract Infection

Summary: lrti (lower respiratory tract infection) is a severe disease in china. the fast and accurate diagnosis of pathogens, bacteria or viruses that cause the infection is critical for the therapy. in this study, investigators assume that the use of filmarray respiratory panel will provide more rapid and comprehensive evidences to physicians to diagnose lrti which is caused by viruses or atypical pathogens and then reduce the length of antibiotics use by 0.5-1.0 days as well as other hospital resources (length of hospital/icu stay, take-away oral antibiotics, etc.). secondly, investigators assume that in lrti patients with viral infection and a low serum pct level, fewer length of antibiotics use can be expected. thirdly, the use of filmarray respiratory panel will provide clearer epidemiology data of virus and atypical pathogens in hospitalized lrti patients.


Eligibility criteria:
inclusion criteria: * adults age \>= 18 years old * community acquired pneumonia, acute exacerbation of chronic obstructive pulmonary disease \[aecopd\], acute exacerbation of bronchiectasis. * hospitalization required * informed consent form signed exclusion criteria: * age \< 18 years old * hospital acquired pneumonia * patients with lung tuberculosis * pregnant women * patients with immunodeficiency * any conditions which may increase pct levels * informed consent form not signed
neuroinflammatory response and headache control in patients after subarachnoid hemorrhage

Conditions: Subarachnoid Hemorrhage, Aneurysmal; Headache; Subarachnoid Hemorrhage

Summary: the purpose of this study is to determine the relationship between the neuroinflammatory response and headache pain after subarachnoid hemorrhage.

persistent headache is a significant medical issue that affects 20% of patients who survive an aneurysmal subarachnoid hemorrhage (sah). this headache may last years, severely affecting quality of life. laboratory evidence suggests that the persistent headache may be a result of a maladaptive neuroinflammatory response to the hemorrhage injury that is more vigorous than necessary. the goal of this study is to measure key immunomodulators in the blood and the cerebrospinal fluid of these patients in order to determine the magnitude and dynamics of their neuroinflammatory response. in addition, the investigators will collect and analyze observational data about the success of medications to treat headache, with a specific focus on the anti-inflammatory agent dexamethasone, in managing acute headache pain and preventing the development of persistent headaches in patients after sah.

Eligibility criteria:
inclusion criteria: * non-traumatic subarachnoid hemorrhage * age \> 18 years * treated with external ventricular drainage exclusion criteria: * pregnancy or lactation * age \< 18 years * traumatic sah

Keywords: headache subarachnoid hemorrhage neuroinflammation
financial incentives to improve medication adherence

Conditions: Schizophrenia; Schizo Affective Disorder; Bipolar Disorder; Depression

Summary: medication adherence is a challenge in all of medicine and is associated with multiple negative outcomes. strategies to better measure and enhance adherence to medication are urgent and necessary to minimize unwanted health outcomes, hospitalizations, poorer quality of life and excessive costs for individuals, insurers and caregivers. recently, behavioral economics-based approaches have emerged as a promising tool to address this unmet need, but its effectiveness in oral antipsychotic treatment remains to be assessed. for this project, investigators will use an app that offers financial incentives to increase compliance for patients with chronic diseases. investigators intend to enroll 25 patients in a pilot project to assess feasibility of offering financial incentives to improve medication adherence in severe mental illness.


Eligibility criteria:
inclusion criteria: 1. psychiatric patients with suspected or confirmed poor oral medication adherence. 2. age 18-80 years old 3. english speaking, since the app being used is only available in english 4. owning a smartphone, since the app requires a smartphone to work 5. willing and able to participate. exclusion criteria: 1. acute anger to self or others as per investigator assessment 2. unwilling or unable to participate

Keywords: financial incentives medication adherence severe mental illness
ofloxacin vs. gentamicin as prophylaxis prior transrectal biopsy of prostate

Conditions: Infection

Summary: prostate biopsy is usually conducted transrectal, ultrasonography guided. since the area is not sterile, infection can be induced during the procedure. prophylaxis antibiotic against gram-negative bacteria decreased significantly the amount of infections. quinolones are considered preferred treatment but there is already an increase in resistance rates. tmp-smx can not be used empirically due to a high percent of resistant uropathogens. one of the options is aminoglycosides, especially gentamicin. advantages: very low resistance rate in the community, high concentration is urinary tract, slow clearance, no resistance developed under treatment, chip and with very few side effects.

prostate biopsy is usually conducted as an ambulatory transrectal needle aspiration, ultrasonography guided. the area is not sterile, with high concentration of gram-negative and anaerobic pathogens, infection can be induced during the procedure to the urinary tract, and even cause bacteremia. prior studies concluded that prophylaxis antibiotic against gram-negative bacteria decreased significantly the amount of infections and hence it is accepted to give prophylaxis antibiotics which will cover especially gram-negative bacteria. other studies show decrease in infections percent in patients that received prophylaxis opposed to those who did not, from 5-30% to less than 1%. yet, there was no significant difference between those who received one dose and those who were treated for 3-5 days. quinolones are considered preferred treatment since they can be given orally, but there is already an increase in resistance rates. tmp-smx can not be used empirically due to a high percent of resistant uropathogens. one of the options is aminoglycosides, especially gentamicin. advantages: very low resistance rate in the community, high concentration is urinary tract, slow clearance, no resistance developed under treatment, chip and with very few side effects.

Eligibility criteria:
inclusion criteria: * patients going under transrectal biopsy of prostate with sterile urine culture. exclusion criteria: * urine culture not sterile

Keywords: transrectal biopsy prostate prophylaxis antibiotic
covid-19 trial of the candidate vaccine mva-sars-2-s in adults

Conditions: Covid19

Summary: in this multi-center phase ii clinical trial, adults in stable health conditions will be vaccinated twice with either a low dose or high dose of the candidate vaccine mva-sars-2-s, or placebo. the aim of the study is to assess the safety and immunogenicity of the candidate vaccine.

the vaccine contains a modified vaccinia virus ankara (mva) vector expressing the sars-cov-2 spike protein (s). this will be a combined phase ii, multi-center trial in a total of 580 participants. the dose finding study will be conducted randomized-controlled, in adults in stable health conditions, including health care workers, covid-19 risk populations, individuals with advanced age and seropositive individuals. male and female individuals in stable health conditions will be stratified for age (18-64 years and 65 and older).

Eligibility criteria:
inclusion criteria: 1. written informed consent. 2. male and female adults in stable health conditions aged 18 - 64 at time of informed consent (participation of health care workers and risk groups will be prioritized) and male or female in stable health conditions aged ≥ 65 at time of informed consent. 3. either in good or stable health in the opinion of the investigator. participants may have underlying illness as long as their symptoms are medically controlled, and they are on a stable medication for the respective underlying illness for at least 8 weeks before screening and no changes are expected during the study. 4. body mass index 18.5 - 32.0 kg/m2 and weight \> 50 kg at screening. 5. non-pregnant, non-lactating female with negative pregnancy test. 6. females who agree to comply with the applicable contraceptive requirements of the protocol. exclusion criteria: 1. receipt of any vaccine from 4 weeks prior to each trial vaccination (8 weeks for live vaccines) to 6 weeks after each trial vaccination. 2. previous rmva immunization. 3. evidence of an active sars-cov-2 infection. 4. known allergy to the components of the mva-sars-2-s vaccine product such as chicken proteins, or history of life-threatening reactions to vaccine containing the same substances. 5. known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine. 6. evidence in the participant's medical history or in the medical examination that might influence either the safety of the participant or the absorption, distribution, metabolism or excretion of the investigational product under investigation. 7. clinically relevant findings in ecg or significant thromboembolic events in medical history. 8. any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic therapy in the previous 5 years, and/or uncontrolled diabetes (hba1c \> 7.0). 9. any known chronic or active neurologic disorder, including seizures, and epilepsy, excluding a single febrile seizure as a child.

Keywords: mva vaccine sars-cov-2